Back

Outcomes associated with modern treatment paradigms in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH): a meta-analysis of randomized controlled trials (RCTs)

1 September 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Advances in the Management of Pulmonary Arterial Hypertension Pulmonary Hypertension ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Vallerie McLaughlin

University of Michigan, Ann Arbor (United States of America)

2 More presentations in this session

Presentation thumbnail
Determinants of pulmonary vascular resistance reduction with upfront oral therapy in idiopathic pulmonary arterial hypertension: relevance in risk assessment
Assistant Professor R. Badagliacca (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil
Doctor R. Sadushi-Kolici (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in the Management of Pulmonary Arterial Hypertension

The Event

Event poster

ESC Congress 2020

1 September 2020 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources